EP
BCRX icon

Eversept Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Eversept Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7M Sell
1,865,653
-1,174,167
-39% -$10.6M 0.97% 30
2026
Q1 		$28.9M Buy
3,039,820
+46,925
+2% +$364K 1.53% 19
2025
Q4 		$23.3M Buy
2,992,895
+1,619,270
+118% +$11.7M 1.18% 20
2025
Q3 		$10.4M Buy
1,373,625
+165,987
+14% +$1.38M 0.72% 34
2025
Q2 		$10.8M Sell
1,207,638
-964,798
-44% -$8.98M 1% 29
2025
Q1 		$16.3M Buy
2,172,436
+192,124
+10% +$1.55M 1.65% 22
2024
Q4 		$14.9M Buy
1,980,312
+1,444,907
+270% +$11M 1.32% 19
2024
Q3 		$4.07M Sell
535,405
-617,168
-54% -$4.69M 0.28% 43
2024
Q2 		$7.12M Sell
1,152,573
-279,854
-20% -$1.54M 0.49% 37
2024
Q1 		$7.28M Sell
1,432,427
-96,620
-6% -$543K 0.49% 40
2023
Q4 		$9.16M Sell
1,529,047
-950,056
-38% -$5.51M 0.8% 28
2023
Q3 		$17.6M Buy
2,479,103
+106,990
+5% +$769K 1.49% 17
2023
Q2 		$16.7M Sell
2,372,113
-2,148,611
-48% -$17.2M 1.4% 18
2023
Q1 		$37.7M Buy
4,520,724
+3,640,237
+413% +$35M 2.63% 12
2022
Q4 		$10.1M Buy
+880,487
New +$11M 0.89% 25
2021
Q1 		– Sell
-491,852
Closed -$3.66M – 91
2020
Q4 		$3.66M Sell
491,852
-651,359
-57% -$3.36M 0.43% 37
2020
Q3 		$3.93M Sell
1,143,211
-3,704,581
-76% -$15.9M 0.87% 28
2020
Q2 		$23.1M Sell
4,847,792
-2,694,580
-36% -$10.8M 3.17% 12
2020
Q1 		$15.1M Buy
7,542,372
+2,637,912
+54% +$7.26M 3.75% 11
2019
Q4 		$16.9M Buy
4,904,460
+4,250,000
+649% +$10.7M 2.99% 12
2019
Q3 		$1.88M Buy
654,460
+312,000
+91% +$970K 0.58% 38
2019
Q2 		$1.3M Sell
342,460
-70,416
-17% -$424K 0.36% 45
2019
Q1 		$3.36M Buy
412,876
+248,917
+152% +$2.13M 0.98% 24
2018
Q4 		$1.32M Buy
163,959
+15,000
+10% +$117K 0.72% 29
2018
Q3 		$1.14M Hold
148,959
– – 0.5% 33
2018
Q2 		$854K Hold
148,959
– – 0.39% 45
2018
Q1 		$711K Sell
148,959
-49,360
-25% -$254K 0.33% 45
2017
Q4 		$974K Buy
+198,319
New +$961K 0.56% 31

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Eversept Partners's BCRX Position: Q2 2026 in Review

Eversept Partners reduced its BioCryst Pharmaceuticals (BCRX) stake by 39% in Q2 2026, selling an estimated $10.6M and leaving 1,865,653 shares worth $18.7M. The position accounts for 0.97% of the portfolio, ranked #30.

Eversept Partners first reported a position in BCRX in Q4 2017 and has held it in 28 quarters since. The position peaked at $37.7M in Q1 2023. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Eversept Partners held 1,865,653 shares of BioCryst Pharmaceuticals worth $18.7M as of Q2 2026.
  • Eversept Partners sold 1,174,167 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $10.6M.
  • BioCryst Pharmaceuticals made up 0.97% of Eversept Partners's portfolio in Q2 2026, its #30 holding.
  • Eversept Partners first reported a position in BioCryst Pharmaceuticals in Q4 2017 and has held it in 28 quarters since.
  • Eversept Partners's BioCryst Pharmaceuticals position peaked at $37.7M in Q1 2023.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.